Cyclic Peptide Inhibitors Modulate USP22 Enzyme Activity
Solution Overview
Problem
Current therapies are ineffective against metastatic cancers characterized by overexpression of USP22, which is associated with poor clinical outcomes, and there is a need for specific inhibitors of deubiquitinating enzymes like USP22 to modulate histone H2B ubiquitination.
Innovation Solution
Development of cyclic peptides that are highly specific inhibitors of USP22, which can modulate histone H2B ubiquitination by targeting the deubiquitinating enzyme USP22, thereby inhibiting its activity and increasing H2B monoubiquitination levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat metastatic cancers with USP22 overexpression, then treatment is provided, but therapeutic effectiveness is poor
Solution Approach 1:
The patent extracts and targets the specific function of USP22 (deubiquitinating enzyme) that causes harmful effects in cancer. By designing cyclic peptides that specifically bind to and inhibit USP22, the invention isolates the problematic enzymatic activity from the complex cellular system, allowing restoration of H2B ubiquitination without affecting other cellular processes.
Solution Approach 2:
The patent changes the biochemical parameter of H2B ubiquitination status by inhibiting USP22. This parameter change (increasing H2B-Ub levels) directly counteracts the harmful effect of USP22 overexpression and restores normal transcriptional regulation, thereby improving therapeutic effectiveness.
2Reliability
If USP22 activity is inhibited to increase H2B monoubiquitination, then transcriptional regulation is improved, but potential off-target effects on other cellular processes may occur
Solution Approach 1:
The patent achieves local specificity by designing cyclic peptides that target the unique structural features of USP22's catalytic domain. The peptide sequence and cyclization pattern are optimized to bind exclusively to USP22's active site, ensuring that only the local function of H2B deubiquitination is affected, while other cellular processes remain unchanged.
Solution Approach 2:
The patent uses cyclic peptide structures that mimic the substrate recognition features of USP22. By creating a simplified peptide copy that reproduces the binding interface characteristics, the invention achieves specific recognition of USP22 without triggering broader cellular responses.
3Measurement precision
If cyclic peptides are designed to be highly specific inhibitors of USP22, then inhibition potency is improved, but peptide stability and pharmacokinetic properties may be compromised
Solution Approach 1:
The patent employs cyclic peptide structures where the peptide backbone is folded back to form a closed loop. This curvature constraint stabilizes the peptide conformation, preventing degradation by proteases while maintaining the specific binding geometry required for high-affinity USP22 inhibition. The cyclization creates a rigid three-dimensional structure that resists structural fluctuations.
Solution Approach 2:
The patent creates composite peptide structures combining specific amino acid sequences with cyclized conformations. This composite design integrates the sequence-specific binding capability with the structural stability provided by cyclization, achieving both high inhibition potency and enhanced pharmacokinetic properties.
Data Source
AI summary
The present disclosure provides peptide inhibitors of Ubiquitin-Specific Protease 22 (USP22), compositions, and methods of use thereof.